ABK Biomedical
ABK Biomedical develops imageable Y90 glass microspheres for liver tumour radioembolization, with visualization during procedures via fluoroscopy, X-ray, and CT.
ABK Biomedical develops imageable Y90 glass microspheres for liver tumour radioembolization, with visualization during procedures via fluoroscopy, X-ray, and CT.
abkbiomedical.comCrawled Oct 16, 2026
The company is studying its lead development product, Eye90 microspheres, in humans for the first time.
Pivotal Study in HCC:: Radioembolization Oncology trial Utilizing Transarterial Eye90 (ROUTE 90) for the treatment of HCC
Up to date repository of ABK Biomedical scientific publications and presentations.
ABK Biomedical's Eye90 microspheres provide a novel approach for treating liver tumors with Y90 radioembolization.
Halifax Office (Main Office) 155 Chain Lake Drive Unit 32 Halifax, NS B3S 1B3 Canada T. 902.442.4009
The page features ABK Biomedical company news and press releases. ABK Biomedical develops products for liver cancer treatment.
The page features press releases from ABK Biomedical, which develops treatments for liver cancer.
ABK Biomedical Awards
The company offers careers in medical devices.
ABK Biomedical's Board bring a wealth of extensive and broad experience to the oversight of ABK Biomedical's operations under Mike Mangano CEO
The ABK Biomedical Leadership team has decades of experience in engineering, material science, oncology, and business development.
ABK Biomedical researches, develops, and commercializes medical devices intended to improve patients’ lives and beat liver tumors.
The company was founded in 2012 as a spin-off from Dalhousie University in Halifax, Nova Scotia, and is preparing to study its lead products in humans.
ABK Biomedical’s careers page provides information about careers and current job openings.
ABK Biomedical focuses on developing Y90 radioembolization treatment options for patients with hypervascular liver tumors.